论文部分内容阅读
选用人膀胱移行细胞癌细胞株BIU－87，通过台盼蓝拒染和3H一胸腺嘧啶掺入实验，研究了异博定对塞替哌及阿霉素的增效作用。结果表明：10mg／L异博定本身无细胞毒作用，与塞替哌及阿霉素并用却显示出了明显增效作用（P＜0．05），但在较低及较高化疗药物组则未显示这种结果（P＞0．05）。10mg／L异博定与塞替哌并用3h显示了增效作用，而与阿霉素并用1h即产生了增效作用（P＜0．05）。随时间的延长，各组增效作用未见明显差异（P＞0．05）。在3H－胸腺嘧啶掺入实验中亦证实了异博定对塞替哌、阿霉素的增效作用（P＜0．05），并与台盼蓝拒染试验结果有很好的相关性γTHP＝0．95，γADN＝0．93）。
The human bladder transitional cell carcinoma cell line BIU-87 was selected for the synergistic effect of isoblocidine on sertaphine and doxorubicin via trypan blue exclusion and 3H-thymidine incorporation experiments. The results showed that 10 mg/L evodipin itself had no cytotoxicity, but showed significant synergistic effects with both tepeter and doxorubicin (P<0.05), but in the lower and higher chemotherapeutic groups. This result was not shown (P>0.05). A synergistic effect was observed with 10 mg/L of isomerdine and sertetol for 3 h, and a synergistic effect was obtained with doxorubicin in combination with 1 h (P<0.05). With the extension of time, there was no significant difference between the synergies of all groups (P>0.05). 3H-thymidine incorporation experiments also confirmed the synergistic effect of isobortidine on sertaphor and doxorubicin (P<0.05), and had a good correlation with the results of the trypan blue exclusion test. γTHP=0.95, γADN=0.93).